-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gilead Sciencerecent recently announced a price tag for remdesivir at $390 a bottle, and most patients are expected to receive a five-day course of treatment for a total of six bottles at a price of $2,340.
investors at least did not seem to be shocked, with Gilead's shares up about 2 percent in early trading.
Gilead says that by helping patients get out of the hospital quickly, Redsewey should be able to immediately save the health care system net costs.
, the only strong Phase III study so far, shows that Redsewe has reduced recovery time by four days (11 days vs 15 days, p.001) compared to placebos;
but the price has drawn criticism from many quarters.
this Phase III project was run by the National Institute of Allergy and Infectious Diseases (NIAID) and was therefore actually paid for by the American taxpayer, some of which believe that taxpayers should get a lower price.
others worry that Redsewe has not yet been shown to reduce the risk of death.
early May, the American Institute for Clinical and Economic Review (ICER) measured Redseweh's pricing and concluded that the $10 price for every 10-day course of treatment would cover production costs, regardless of investment in research and development, and that a $4,500 price would be considered cost-effective if the benefits of death were clarified.
Related Read: Redsee Wey commercialization in the instant, Gilead odds geometry? A new analysis recently conducted by ICER found That Redsewe's $2,500-$2,800 price was cost-effective, slightly higher than Gilead's own.
however, the ICER analysis assumes two very important factors: the inclusion of the steroid drug dexamethasone as a standard care, and the other is that Redsewe shows the benefits of death.
the first factor seems likely to happen, with one study finding that the cheap steroid can reduce the mortality rate of patients with COVID-19 severe ventilation by a third.
, however, the second factor is far from assured.
in the ACTT study, NIAID found that the Redsewe group had lower mortality rates on the 14th day than the placebo group (8% vs 12%), but the difference sharply did not show a statistically significant;
ICER concluded that if the benefits of death were not shown, Redsewe's cost-effectiveness benchmark would have fallen to $310.
if positive signs of this survival benefit were not consistently present in Redseywe's clinical studies, Gilead may find it harder to get rid of criticism of its pricing.
Despite this, seller analysts now have a price to simulate future sales. The chart above the
, from EvaluatePharma, shows the current seller consensus, which includes some very different numbers.
this partly reflects different perceptions of demand and prices in Redsewe, which were also pre-edifying the study of CAVID-19 in dexamethasone therapy.
SVB Leerink's report said Gilead's pricing for Redsewey fell short of its expectations, though analysts still expected Gilead to make a profit from Redsewe. Analysts at Sun Trust Robinson,
, are sceptical that redside has spent $1bn on investments this year alone, and how can Gilead recover its investment in the short term? Gilead and its investors also want to recover costs as soon as possible.
Given that progress in the COVID-19 pandemic and other potential therapies remains unknown, this means that Redsewe's pricing needs to be as high as possible.
it's worth noting that on the 20th of this month, two Redsiwel generics were approved for sale in India, from Cipremi and Covifor, which are priced at $39-$52 each and $65-$78 each.
Under current guidelines of the Indian government, a case of COVID-19 patients may need to take 5-6 doses, which means the total cost of the entire course of antiviral therapy in Redsivir could be as low as $195.
Related Read: Redseve generic drug approved in India, with total treatment costs as low as $195! Source: Gilead Final prices its Covid-19 drug.